Singapore markets close in 5 hours 17 minutes

LLY Jul 2024 950.000 call

OPR - OPR Delayed price. Currency in USD
Add to watchlist
5.50-0.95 (-14.73%)
As of 03:17PM EDT. Market open.
Full screen
Previous close6.45
Open6.05
Bid4.50
Ask5.85
Strike950.00
Expiry date2024-07-19
Day's range5.10 - 6.18
Contract rangeN/A
Volume56
Open interest418
  • Zacks

    Alzheimer's in Focus as FDA Panel Endorses Lilly's Donanemab

    If Eli Lilly's (LLY) donanemab is approved by the FDA, it will become the second drug approved by the FDA to reduce the clinical decline associated with Alzheimer's disease.

  • Yahoo Finance Video

    Oil prices, National Amusement ends Skydance talks: Market Domination

    It's just an hour to the end of the trading day and the clock is ticking! Market Domination Hosts Julie Hyman and Josh Lipton guide investors through the home stretch all the way to the market close, breaking down leading market stories and top trending stocks. Path Trading Partners Co-Founder and Chief Market Strategist Bob Iaccino provides context as to where oil (CL=F, BZ=F) and gas prices (RB=F) could be headed this summer due to OPEC+'s production cuts. Apple (AAPL) is no short-supply of opportunities this week as Affirm (AFRM) is partnering with the tech giant to integrate buy now, pay later (BNPL) loans into Apple Pay. Needham Senior Media and Internet Analyst Laura Martin explains where she stands on Apple entering the AI race so late into the game. This post was written by Luke Carberry Mogan.

  • Yahoo Finance Video

    Eli Lilly's new Alzheimer's treatment could 'lift' drug market

    Eli Lilly (LLY) is one step closer to getting its new Alzheimer's treatment approved by the Food and Drug Administration (FDA) after a panel voted to recommend its use. BMO Capital Markets Managing Director Evan Seigerman joins Market Domination to discuss how the drug will fit into the drug market. Seigerman explains, "Investors have been hoping that the addition of another product, Lilly's donanemab, could kind of help lift the entire market because having two products and basically three companies marketing the class should accelerate uptake." He expects approval to be near-term but notes that the challenges of getting a diagnosis and the infrastructure involved could make it difficult for patients to access treatment. For more expert insight and the latest market action, click here to watch this full episode of Market Domination. This post was written and updated by Melanie Riehl